QR-6401

N/A

Report date: 2023/11/15 17:29:48
NME

Base Information

Drug NameQR-6401
Drug Alias NameQR-6401
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 2
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTencent Ai LabQILU Regor Therapeutics IncBioduro-Sundia
China Registration ClassN/A

Develop Information

Active CompaniesTencent Ai LabQILU Regor Therapeutics IncBioduro-Sundia
Inactive CompaniesN/A
Active IndicationsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A